세계의 테라노스틱스 시장 규모, 점유율, 동향 분석 리포트 : 최종사용자별, 제품별, 용도별, 지역별 전망과 예측(2023-2030년)

The Global Theranostics Market size is expected to reach $5.4 billion by 2030, rising at a market growth of 15.2% CAGR during the forecast period.

North America boasts a well-developed healthcare infrastructure with modern hospitals, diagnostic centers, and research institutions with state-of-the-art medical technologies. Therefore, the North America region captured $782.9 million revenue in the market in 2022. The availability of advanced diagnostic imaging modalities, molecular diagnostic laboratories, and therapeutic facilities enables the adoption and integration of theranostic approaches into clinical practice.

Targeted therapies align with the principles of precision medicine, which emphasize the customization of healthcare interventions based on individual patient characteristics, including genetic makeup, biomarker expression profiles, and disease phenotypes. Targeting specific molecular alterations or disease pathways, targeted therapies offer personalized treatment strategies tailored to individual patient's unique genetic and molecular profiles. Therefore, innovation in targeted therapies is propelling the growth of the market.

Additionally, radiopharmaceuticals possess dual capabilities for diagnostic imaging and targeted therapy, making them ideal candidates for theranostic applications. Radiopharmaceuticals can be labeled with radioactive isotopes that emit gamma rays for diagnostic imaging (e.g., positron emission tomography or single-photon emission computed tomography) and beta particles for therapeutic purposes (e.g., radioimmunotherapy or targeted radionuclide therapy). Hence, rapid growth in radiopharmaceuticals is driving the growth of the market.

However, theranostic approaches often involve integrating sophisticated technologies, including molecular diagnostics, imaging modalities, targeted therapies, and drug delivery systems. Developing and implementing these technologies require specialized expertise in multiple disciplines, such as biology, chemistry, physics, and engineering. Hence, technical complexity hampers the growth of the market.

During the initial stages of the pandemic, healthcare resources and priorities shifted towards managing and controlling the spread of COVID-19. This diversion of resources and focus away from non-urgent medical procedures, including diagnostic imaging and personalized medicine initiatives, temporarily slowed the adoption and implementation of theranostic technologies in clinical practice. Also, the COVID-19 pandemic disrupted global supply chains, affecting the availability and distribution of theranostic products, components, and raw materials. Therefore, the COVID-19 pandemic had a negative impact on the market.

By End User Analysis

Based on end user, the market is categorized into hospitals & cancer care centers, theranostics centers, and research & academic centers. In 2022, the hospitals & cancer care centers segment registered 50.3% revenue share in the market. Hospitals and cancer care centers serve as hubs for comprehensive healthcare services, offering various diagnostic, therapeutic, and supportive care options for patients with complex medical conditions like cancer.

By Product Analysis

Based on product, the market is divided into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software & services. In 2022, the diagnostic imaging segment garnered 30.5% revenue share in the market. Diagnostic imaging provides valuable treatment planning and guidance information by visualizing disease extent, localization, and staging.

By Application Analysis

On the basis of application, the market is segmented into prostate cancer, bone metastasis, other cancers, and others. The prostate cancer segment recorded 38.1% revenue share in the market in 2022. Prostate cancer exhibits significant heterogeneity in terms of disease aggressiveness, treatment response, and patient outcomes. Theranostic approaches allow for personalizing treatment strategies based on individual patient characteristics and tumor biology.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated 23.0% revenue share in the market. The Asia Pacific region is experiencing a rising burden of chronic diseases, including cancer, cardiovascular diseases, and metabolic disorders, due to aging populations, urbanization, and changing lifestyles.

List of Key Companies Profiled

• Bayer AG
• GE HealthCare Technologies, Inc.
• Siemens Healthineers AG (Siemens AG)
• Cardinal Health, Inc.
• Canon, Inc.
• Clarity Pharmaceuticals Ltd
• Koninklijke Philips N.V.
• Thermo Fisher Scientific, Inc.
• Telix Pharmaceuticals Limited
• ABX advanced biochemical compounds GmbH

Global Theranostics Market Report Segmentation

By End User

• Hospitals & Cancer Care Centers
• Theranostics Centers
• Research & Academic Centers

By Product

• Radiopharmaceuticals
• Diagnostic Imaging
• IVD/Biomarker Screening
• Software & Services

By Application

• Prostate Cancer
• Bone Metastasis
• Other Cancers
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Theranostics Market, by End User
  • 1.4.2Global Theranostics Market, by Product
  • 1.4.3Global Theranostics Market, by Application
  • 1.4.4Global Theranostics Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Restraints
  • 3.2.3Market Opportunities
  • 3.2.4Market Challenges
• 3.3Porter's Five Forces Analysis

Chapter 4.Global Theranostics Market by End User

• 4.1Global Hospitals & Cancer Care Centers Market by Region
• 4.2Global Theranostics Centers Market by Region
• 4.3Global Research & Academic Centers Market by Region

Chapter 5.Global Theranostics Market by Product

• 5.1Global Radiopharmaceuticals Market by Region
• 5.2Global Diagnostic Imaging Market by Region
• 5.3Global IVD/Biomarker Screening Market by Region
• 5.4Global Software & Services Market by Region

Chapter 6.Global Theranostics Market by Application

• 6.1Global Prostate Cancer Market by Region
• 6.2Global Bone Metastasis Market by Region
• 6.3Global Other Cancers Market by Region
• 6.4Global Others Market by Region

Chapter 7.Global Theranostics Market by Region

• 7.1North America Theranostics Market
  • 7.1.1North America Theranostics Market by End User
    • 7.1.1.1North America Hospitals & Cancer Care Centers Market by Country
    • 7.1.1.2North America Theranostics Centers Market by Country
    • 7.1.1.3North America Research & Academic Centers Market by Country
  • 7.1.2North America Theranostics Market by Product
    • 7.1.2.1North America Radiopharmaceuticals Market by Country
    • 7.1.2.2North America Diagnostic Imaging Market by Country
    • 7.1.2.3North America IVD/Biomarker Screening Market by Country
    • 7.1.2.4North America Software & Services Market by Country
  • 7.1.3North America Theranostics Market by Application
    • 7.1.3.1North America Prostate Cancer Market by Country
    • 7.1.3.2North America Bone Metastasis Market by Country
    • 7.1.3.3North America Other Cancers Market by Country
    • 7.1.3.4North America Others Market by Country
  • 7.1.4North America Theranostics Market by Country
    • 7.1.4.1US Theranostics Market
      • 7.1.4.1.1US Theranostics Market by End User
      • 7.1.4.1.2US Theranostics Market by Product
      • 7.1.4.1.3US Theranostics Market by Application
    • 7.1.4.2Canada Theranostics Market
      • 7.1.4.2.1Canada Theranostics Market by End User
      • 7.1.4.2.2Canada Theranostics Market by Product
      • 7.1.4.2.3Canada Theranostics Market by Application
    • 7.1.4.3Mexico Theranostics Market
      • 7.1.4.3.1Mexico Theranostics Market by End User
      • 7.1.4.3.2Mexico Theranostics Market by Product
      • 7.1.4.3.3Mexico Theranostics Market by Application
    • 7.1.4.4Rest of North America Theranostics Market
      • 7.1.4.4.1Rest of North America Theranostics Market by End User
      • 7.1.4.4.2Rest of North America Theranostics Market by Product
      • 7.1.4.4.3Rest of North America Theranostics Market by Application
• 7.2Europe Theranostics Market
  • 7.2.1Europe Theranostics Market by End User
    • 7.2.1.1Europe Hospitals & Cancer Care Centers Market by Country
    • 7.2.1.2Europe Theranostics Centers Market by Country
    • 7.2.1.3Europe Research & Academic Centers Market by Country
  • 7.2.2Europe Theranostics Market by Product
    • 7.2.2.1Europe Radiopharmaceuticals Market by Country
    • 7.2.2.2Europe Diagnostic Imaging Market by Country
    • 7.2.2.3Europe IVD/Biomarker Screening Market by Country
    • 7.2.2.4Europe Software & Services Market by Country
  • 7.2.3Europe Theranostics Market by Application
    • 7.2.3.1Europe Prostate Cancer Market by Country
    • 7.2.3.2Europe Bone Metastasis Market by Country
    • 7.2.3.3Europe Other Cancers Market by Country
    • 7.2.3.4Europe Others Market by Country
  • 7.2.4Europe Theranostics Market by Country
    • 7.2.4.1Germany Theranostics Market
      • 7.2.4.1.1Germany Theranostics Market by End User
      • 7.2.4.1.2Germany Theranostics Market by Product
      • 7.2.4.1.3Germany Theranostics Market by Application
    • 7.2.4.2UK Theranostics Market
      • 7.2.4.2.1UK Theranostics Market by End User
      • 7.2.4.2.2UK Theranostics Market by Product
      • 7.2.4.2.3UK Theranostics Market by Application
    • 7.2.4.3France Theranostics Market
      • 7.2.4.3.1France Theranostics Market by End User
      • 7.2.4.3.2France Theranostics Market by Product
      • 7.2.4.3.3France Theranostics Market by Application
    • 7.2.4.4Russia Theranostics Market
      • 7.2.4.4.1Russia Theranostics Market by End User
      • 7.2.4.4.2Russia Theranostics Market by Product
      • 7.2.4.4.3Russia Theranostics Market by Application
    • 7.2.4.5Spain Theranostics Market
      • 7.2.4.5.1Spain Theranostics Market by End User
      • 7.2.4.5.2Spain Theranostics Market by Product
      • 7.2.4.5.3Spain Theranostics Market by Application
    • 7.2.4.6Italy Theranostics Market
      • 7.2.4.6.1Italy Theranostics Market by End User
      • 7.2.4.6.2Italy Theranostics Market by Product
      • 7.2.4.6.3Italy Theranostics Market by Application
    • 7.2.4.7Rest of Europe Theranostics Market
      • 7.2.4.7.1Rest of Europe Theranostics Market by End User
      • 7.2.4.7.2Rest of Europe Theranostics Market by Product
      • 7.2.4.7.3Rest of Europe Theranostics Market by Application
• 7.3Asia Pacific Theranostics Market
  • 7.3.1Asia Pacific Theranostics Market by End User
    • 7.3.1.1Asia Pacific Hospitals & Cancer Care Centers Market by Country
    • 7.3.1.2Asia Pacific Theranostics Centers Market by Country
    • 7.3.1.3Asia Pacific Research & Academic Centers Market by Country
  • 7.3.2Asia Pacific Theranostics Market by Product
    • 7.3.2.1Asia Pacific Radiopharmaceuticals Market by Country
    • 7.3.2.2Asia Pacific Diagnostic Imaging Market by Country
    • 7.3.2.3Asia Pacific IVD/Biomarker Screening Market by Country
    • 7.3.2.4Asia Pacific Software & Services Market by Country
  • 7.3.3Asia Pacific Theranostics Market by Application
    • 7.3.3.1Asia Pacific Prostate Cancer Market by Country
    • 7.3.3.2Asia Pacific Bone Metastasis Market by Country
    • 7.3.3.3Asia Pacific Other Cancers Market by Country
    • 7.3.3.4Asia Pacific Others Market by Country
  • 7.3.4Asia Pacific Theranostics Market by Country
    • 7.3.4.1China Theranostics Market
      • 7.3.4.1.1China Theranostics Market by End User
      • 7.3.4.1.2China Theranostics Market by Product
      • 7.3.4.1.3China Theranostics Market by Application
    • 7.3.4.2Japan Theranostics Market
      • 7.3.4.2.1Japan Theranostics Market by End User
      • 7.3.4.2.2Japan Theranostics Market by Product
      • 7.3.4.2.3Japan Theranostics Market by Application
    • 7.3.4.3India Theranostics Market
      • 7.3.4.3.1India Theranostics Market by End User
      • 7.3.4.3.2India Theranostics Market by Product
      • 7.3.4.3.3India Theranostics Market by Application
    • 7.3.4.4South Korea Theranostics Market
      • 7.3.4.4.1South Korea Theranostics Market by End User
      • 7.3.4.4.2South Korea Theranostics Market by Product
      • 7.3.4.4.3South Korea Theranostics Market by Application
    • 7.3.4.5Singapore Theranostics Market
      • 7.3.4.5.1Singapore Theranostics Market by End User
      • 7.3.4.5.2Singapore Theranostics Market by Product
      • 7.3.4.5.3Singapore Theranostics Market by Application
    • 7.3.4.6Malaysia Theranostics Market
      • 7.3.4.6.1Malaysia Theranostics Market by End User
      • 7.3.4.6.2Malaysia Theranostics Market by Product
      • 7.3.4.6.3Malaysia Theranostics Market by Application
    • 7.3.4.7Rest of Asia Pacific Theranostics Market
      • 7.3.4.7.1Rest of Asia Pacific Theranostics Market by End User
      • 7.3.4.7.2Rest of Asia Pacific Theranostics Market by Product
      • 7.3.4.7.3Rest of Asia Pacific Theranostics Market by Application
• 7.4LAMEA Theranostics Market
  • 7.4.1LAMEA Theranostics Market by End User
    • 7.4.1.1LAMEA Hospitals & Cancer Care Centers Market by Country
    • 7.4.1.2LAMEA Theranostics Centers Market by Country
    • 7.4.1.3LAMEA Research & Academic Centers Market by Country
  • 7.4.2LAMEA Theranostics Market by Product
    • 7.4.2.1LAMEA Radiopharmaceuticals Market by Country
    • 7.4.2.2LAMEA Diagnostic Imaging Market by Country
    • 7.4.2.3LAMEA IVD/Biomarker Screening Market by Country
    • 7.4.2.4LAMEA Software & Services Market by Country
  • 7.4.3LAMEA Theranostics Market by Application
    • 7.4.3.1LAMEA Prostate Cancer Market by Country
    • 7.4.3.2LAMEA Bone Metastasis Market by Country
    • 7.4.3.3LAMEA Other Cancers Market by Country
    • 7.4.3.4LAMEA Others Market by Country
  • 7.4.4LAMEA Theranostics Market by Country
    • 7.4.4.1Brazil Theranostics Market
      • 7.4.4.1.1Brazil Theranostics Market by End User
      • 7.4.4.1.2Brazil Theranostics Market by Product
      • 7.4.4.1.3Brazil Theranostics Market by Application
    • 7.4.4.2Argentina Theranostics Market
      • 7.4.4.2.1Argentina Theranostics Market by End User
      • 7.4.4.2.2Argentina Theranostics Market by Product
      • 7.4.4.2.3Argentina Theranostics Market by Application
    • 7.4.4.3UAE Theranostics Market
      • 7.4.4.3.1UAE Theranostics Market by End User
      • 7.4.4.3.2UAE Theranostics Market by Product
      • 7.4.4.3.3UAE Theranostics Market by Application
    • 7.4.4.4Saudi Arabia Theranostics Market
      • 7.4.4.4.1Saudi Arabia Theranostics Market by End User
      • 7.4.4.4.2Saudi Arabia Theranostics Market by Product
      • 7.4.4.4.3Saudi Arabia Theranostics Market by Application
    • 7.4.4.5South Africa Theranostics Market
      • 7.4.4.5.1South Africa Theranostics Market by End User
      • 7.4.4.5.2South Africa Theranostics Market by Product
      • 7.4.4.5.3South Africa Theranostics Market by Application
    • 7.4.4.6Nigeria Theranostics Market
      • 7.4.4.6.1Nigeria Theranostics Market by End User
      • 7.4.4.6.2Nigeria Theranostics Market by Product
      • 7.4.4.6.3Nigeria Theranostics Market by Application
    • 7.4.4.7Rest of LAMEA Theranostics Market
      • 7.4.4.7.1Rest of LAMEA Theranostics Market by End User
      • 7.4.4.7.2Rest of LAMEA Theranostics Market by Product
      • 7.4.4.7.3Rest of LAMEA Theranostics Market by Application

Chapter 8.Company Profiles

• 8.1Bayer AG
  • 8.1.1Company Overview
  • 8.1.2Financial Analysis
  • 8.1.3Segmental and Regional Analysis
  • 8.1.4Research & Development Expense
  • 8.1.5Recent strategies and developments:
    • 8.1.5.1Acquisition and Mergers:
  • 8.1.6SWOT Analysis
• 8.2GE HealthCare Technologies, Inc.
  • 8.2.1Company Overview
  • 8.2.2Financial Analysis
  • 8.2.3Segmental and Regional Analysis
  • 8.2.4Research & Development Expenses
  • 8.2.5Recent strategies and developments:
    • 8.2.5.1Partnerships, Collaborations, and Agreements:
  • 8.2.6SWOT Analysis
• 8.3Siemens Healthineers AG (Siemens AG)
  • 8.3.1Company Overview
  • 8.3.2Financial Analysis
  • 8.3.3Segmental and Regional Analysis
  • 8.3.4Research & Development Expense
  • 8.3.5Recent strategies and developments:
    • 8.3.5.1Product Launches and Product Expansions:
  • 8.3.6SWOT Analysis
• 8.4Cardinal Health, Inc.
  • 8.4.1Company Overview
  • 8.4.2Financial Analysis
  • 8.4.3Segmental and Regional Analysis
  • 8.4.4SWOT Analysis
• 8.5Canon, Inc.
  • 8.5.1Company Overview
  • 8.5.2Financial Analysis
  • 8.5.3Segmental and Regional Analysis
  • 8.5.4Research & Development Expenses
  • 8.5.5SWOT Analysis
• 8.6Clarity Pharmaceuticals Ltd
  • 8.6.1Company Overview
  • 8.6.2Financial Analysis
  • 8.6.3Research & Development Expenses
  • 8.6.4SWOT Analysis
• 8.7Koninklijke Philips N.V.
  • 8.7.1Company Overview
  • 8.7.2Financial Analysis
  • 8.7.3Segmental and Regional Analysis
  • 8.7.4Research & Development Expense
  • 8.7.5SWOT Analysis
• 8.8Thermo Fisher Scientific, Inc.
  • 8.8.1Company Overview
  • 8.8.2Financial Analysis
  • 8.8.3Segmental and Regional Analysis
  • 8.8.4Research & Development Expenses
  • 8.8.5SWOT Analysis
• 8.9Telix Pharmaceuticals Limited
  • 8.9.1Company Overview
  • 8.9.2Financial Analysis
  • 8.9.3Segmental and Regional Analysis
  • 8.9.4Research & Development Expenses
  • 8.9.5SWOT Analysis
• 8.10.ABX advanced biochemical compounds GmbH
  • 8.10.1Company Overview
  • 8.10.2SWOT Analysis

Chapter 9.Winning Imperatives of Theranostics Market